Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 6Other solid neoplasm 5Other hematologic neoplasm 5Gastrointestinal 5Breast 4Thoracic 2Lymphoid 2Head & Neck 2Dermatologic 2Tumor-Agnostic 1Other 1Myeloid 1Gynecologic 1CNS 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 22fludarabine 20Cyclophosphamide 20Biopsy 19fludarabine phosphate 15Cytarabine 13Whole-Body Irradiation 11Mycophenolic Acid 11Busulfan 11Tacrolimus 10Melphalan 10venetoclax 9X-Rays 9decitabine and cedazuridine drug combination 8Magnetic Resonance Spectroscopy 8Injections 8Cyclosporine 8asciminib 7Sirolimus 7Granulocyte Colony-Stimulating Factor 7Thiotepa 6Nuclear Medicine Department, Hospital 6Azacitidine 6ruxolitinib 5Stem Cell Transplantation 5Phantoms, Imaging 5Peripheral Blood Stem Cell Transplantation 5Idarubicin 5Filgrastim 5CPX-351 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Practice Guidelines as Topic × Myeloid × 30 days × Clear all
NCT05564390 2026-06-03

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡